Alessandro Pileri - Concepedia

Author

Alessandro Pileri

Also Known As

A PILERI, A Pileri, A Pileri Jr, A. PILERI, A. Pileri, A. Pileri Jr., A.A. Pileri, ALESSANDRO PILERI, AlessandRo Pileri, Alessandro PILERI

581

Publications

13.7K

Citations

H-Index

121

Concepts

All Affiliations

University of Turin Azienda Ospedaliero Universitaria San Giovanni Battista University of Bologna Fondazione IRCCS Istituto Nazionale dei Tumori Fondazione Ricerca Molinette

About

Alessandro Pileri is an author at University of Turin specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	78	4.8K
2	Health Sciences	17	28	1.4K
3	Allergy	4	4	156
4	Natural Sciences	3	3	54
5	Language Studies	1	1	28

Alessandro Pileri

162

Publications

11K

Citations

H-Index

Page 1

	Year	Citations
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION AlessandroM. Gianni, Marco Bregni, A. Stern, The Lancet TransplantationMarrow TransplantationStem Cell MobilizationStem Cell TransplantationImmunology	1989	750
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients Stefano Pileri, Stefano Ascani, Maria Christina Cox, Leukemia Hematological MalignancyCytogenetic AnalysisMedicineAdult PatientsHematology	2006	694
High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma Alessandro M. Gianni, Marco Bregni, Salvatore Siena, New England Journal of Medicine	1997	478
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials Stefano Pasquali, J D Maqueo, Jorge Espino Vela, Oxford University Research Archive (ORA) (University of Oxford) Hematological MalignancyOncologyMetronomic TherapyImmunologyRandomized Trials	1998	473
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model Julia Scarisbrick, H. Miles Prince, Maarten H. Vermeer, Journal of Clinical Oncology	2015	407
Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy Franco Mandelli, Giuseppe Avvisati, Sergio Amadori, New England Journal of Medicine	1990	385
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system Régis Bataille, Mario Boccadoro, Bernard Klein, Blood	1992	288
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage Marco Ladetto, Federica De Marco, Fabio Benedetti, Blood	2008	253
Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells Paolo Corradini, Claudia Voena, Corrado Tarella, Journal of Clinical Oncology	1999	242
Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas Pier Luigi Zinzani, Pietro Quaglino, Nicola Pimpinelli, Journal of Clinical Oncology	2006	228

Page 1